Absci Corp (NASDAQ: ABSI) is a clinical-stage biopharmaceutical company that uses an AI-native approach to develop antibody therapeutics. Revenue comes from partner program fees, including up-front fees, research fees, and potential milestone and royalty payments from drug creation collaborations, though the company remains pre-commercial. Partner program revenue was $2.8 million in FY2025, down from $4.5 million in FY2024, while the net loss widened to $115.2 million in FY2025 from $103.1 million in FY2024. The platform combines Origin-1, a generative design model, with a lab-in-the-loop validation system to design antibody-based therapeutics. Lead internal program ABS-201 is advancing toward clinical development, with additional preclinical programs targeted for partnership or out-licensing. As of December 31, 2025, Absci had 140 employees, the majority engaged in research and development. Sean McClain, co-founder and CEO, leads the company alongside CFO and Chief Business Officer Zachariah Jonasson.

Revenue model

Partner program revenue from drug creation collaborations, including up-front fees and research fees, plus potential clinical and commercial milestone payments and royalties. FY2025 partner program revenue was $2.8 million; FY2024 was $4.5 million. The company is pre-commercial on its internally developed pipeline and funds operations primarily from cash reserves and marketable securities.

Products and services

Integrated Drug Creation platform combining Origin-1 (generative AI design model) and a lab-in-the-loop wet-lab validation system. Internally developed pipeline led by ABS-201, a clinical-stage antibody therapeutic. Additional preclinical programs generated via de novo antibody design, multi-parameter candidate optimization, and reverse immunology approaches. Partnered programs structured as drug creation collaborations or co-development partnerships.

Customers and end markets

Biopharmaceutical and pharmaceutical partners seeking AI-assisted antibody drug discovery and development. End markets are therapeutic areas with high unmet medical need and underexplored biological mechanisms. The company also pursues out-licensing arrangements for select pipeline assets.

Value-chain role

Drug discovery and preclinical development platform provider. Absci sits at the early research and development stage of the pharmaceutical value chain, generating candidate antibodies and advancing them to value inflection points before partnering, out-licensing, or pursuing independent clinical development.

Source: SEC 10-K, filed 2026-03-24

Industry: Services-Commercial Physical & Biological Research Peers: Akoya Biosciences, Inc. Nautilus Biotechnology Inc Bruker Cellular Analysis, Inc. Inotiv Inc Codexis Inc Quantum-Si Inc Science 37 Holdings, Inc. Quanterix Corp Singular Genomics Systems, Inc. Thermo Fisher Scientific Inc